SNTI vs. DYAI, TARA, LENZ, CDTX, ALGS, INAB, OKYO, BCLI, ACHL, and CYTH
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Dyadic International (DYAI), Protara Therapeutics (TARA), LENZ Therapeutics (LENZ), Cidara Therapeutics (CDTX), Aligos Therapeutics (ALGS), IN8bio (INAB), OKYO Pharma (OKYO), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), and Cyclo Therapeutics (CYTH). These companies are all part of the "biological products, except diagnostic" industry.
Dyadic International (NASDAQ:DYAI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
In the previous week, Dyadic International had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Dyadic International and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.95 beat Dyadic International's score of 0.93 indicating that Dyadic International is being referred to more favorably in the media.
Dyadic International received 155 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 63.97% of users gave Dyadic International an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote.
Dyadic International has higher revenue and earnings than Senti Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Dyadic International has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.88, suggesting that its share price is 188% more volatile than the S&P 500.
Dyadic International has a net margin of -347.92% compared to Dyadic International's net margin of -2,692.82%. Dyadic International's return on equity of -79.71% beat Senti Biosciences' return on equity.
Dyadic International currently has a consensus price target of $6.00, suggesting a potential upside of 175.23%. Senti Biosciences has a consensus price target of $6.00, suggesting a potential upside of 1,900.00%. Given Dyadic International's higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Dyadic International.
28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Dyadic International beats Senti Biosciences on 11 of the 16 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
